循环肿瘤DNA在B细胞非霍奇金淋巴瘤中的研究进展  

Progress of circulating tumor DNA in B-cell non-Hodgkin lymphoma

作　　者：宋妮妮 盛立霞 欧阳桂芳[1] Song Nini;Sheng Lixia;Ouyang Guifang(Department of Hematology, Ningbo First Hospital Affiliated to Ningbo University, Ningbo 315000, China)

机构地区：[1]宁波大学附属宁波市第一医院血液科,315000

出　　处：《白血病．淋巴瘤》2019年第5期305-308,共4页Journal of Leukemia & Lymphoma

摘　　要：从分子水平监测非霍奇金淋巴瘤(NHL)患者的疾病状态对精准的个体化管理具有重要意义。基于新型二代测序的方法能够以极高的灵敏度从外周血中定量检测循环肿瘤DNA(ctDNA),其可克服活组织检查和成像扫描的弊端,作为NHL的新型生物标志物,为治疗前、治疗期间和治疗后的疾病精准分型、预后评估、疗效判断以及复发监测带来新的机遇,并可能最终改善患者预后。Monitoring the disease status of the patients with non-Hodgkin lymphoma (NHL) at the molecular level is of great significance in the accurate individualized management. The novel next generation sequencing-based methods enable the quantitative detection of circulating tumor DNA (ctDNA) in peripheral blood with great sensitivity, which can overcome the shortages of biopsies and imaging scans. As a new biomarker of NHL, ctDNA provides the opportunity for disease genotyping, prognosis evaluation, therapeutic response and recurrence monitoring, which may ultimately improve the prognosis of NHL patients.

关 键 词：淋巴瘤 非霍奇金 循环肿瘤DNA 分子监测 

分 类 号：R733.1[医药卫生—肿瘤]